ClinicalTrials.gg
CompletedNCT07422285Updated Aug 17, 2026

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

A Phase 1 interventional study of Evolocumab Drug Substance A and Evolocumab Drug Substance B in Healthy Participants and Pharmacokinetics, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.

02

Conditions studied

  • Healthy Participants
  • Pharmacokinetics

Keywords

  • Evolocumab
  • AMG 145
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, of any race, between 18 and 60 years of age, inclusive.

    a. Females must not be pregnant or lactating.

  2. (BMI) between 18.0 and 32.0 kg/m\^2 inclusive.
  3. LDL-C level ≥ 70 mg/dL (1.8 mmol/L) and ≤ 190 mg/dL (4.9 mmol/L) at screening.

Exclusion criteria

Exclusion Criteria

  1. History or evidence of any disorder, condition, or disease that in the opinion of the investigator (or designee) would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
  2. History or current signs or symptoms of cardiovascular disease.
  3. History or evidence of clinically significant arrhythmia.
  4. History of , intolerance, or allergy to evolocumab or its ingredients or other biological drugs.
  5. Uncontrolled hyperthyroidism or hypothyroidism.
  6. Current use or prior use of over-the-counter or other prescription medications, herbal medicines, vitamins, and supplements within 30 days or 5 half-lives prior to check-in.
  7. Participation in another device or drug trial within the past 30 days or 5 half-lives prior to check-in.
  8. Have previously completed or withdrawn from this trial or any other trial investigating evolocumab, any other product directed against PCSK9, or have previously received evolocumab or PCSK9 inhibitor.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Evolocumab Drug Substance A

    Participants will receive a single subcutaneous (SC) dose of evolocumab drug substance A.

    Drug: Evolocumab Drug Substance A

  • Experimental
    Evolocumab Drug Substance B

    Participants will receive a single SC dose of evolocumab drug substance B.

    Drug: Evolocumab Drug Substance B

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve (AUC) from Time 0 Extrapolated to Infinity (AUCinf) of Evolocumab

    Time frame: Day 1 to Day 64

  2. Area Under the Concentration-time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of Evolocumab

    Time frame: Day 1 to Day 64

  3. Maximum Observed Concentration (Cmax) of Evolocumab

    Time frame: Day 1 to Day 64

Secondary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events

    Time frame: Day 1 to Day 64

  2. Number of Participants with Serious Adverse Events

    Time frame: Up to Day 64

  3. Number of Participants with Anti-evolocumab Antibody Formation

    Time frame: Day 1 and Day 64

  4. Area Under the Effect Curve From Day 1 through Day 64 (AUECDay1-Day64) of Low-density Lipoprotein Cholesterol (LDL-C)

    Time frame: Day 1 to Day 64

  5. Serum Levels of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

    Time frame: Day 1 to Day 64

07

Study locations

4 sites
  • QPS Bio-Kinetic
    Springfield, Missouri 65802-4842, United States
  • Ohio Clinical Trials, Inc.
    Columbus, Ohio 43212, United States
  • Fortrea Clinical Research Unit - Dallas
    Dallas, Texas 75247, United States
  • Fortrea Clinical Research Unit Inc. - Madison
    Madison, Wisconsin 53704-2526, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Jul 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 20, 2026
StartActual
Jan 16, 2026
Primary completionActual
Jul 24, 2026
CompletionActual
Jul 24, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422285
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Jan 16, 2026
Primary completion
Jul 24, 2026
Completion
Jul 24, 2026
Last update
Aug 17, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion